Cargando…

Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size

BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Fumiya, Shibamoto, Yuta, Ogino, Hiroyuki, Murata, Rumi, Sugie, Chikao, Iwata, Hiromitsu, Otsuka, Shinya, Kosaki, Katsura, Nagai, Aiko, Murai, Taro, Miyakawa, Akifumi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955592/
https://www.ncbi.nlm.nih.gov/pubmed/20849623
http://dx.doi.org/10.1186/1748-717X-5-81
_version_ 1782188046580449280
author Baba, Fumiya
Shibamoto, Yuta
Ogino, Hiroyuki
Murata, Rumi
Sugie, Chikao
Iwata, Hiromitsu
Otsuka, Shinya
Kosaki, Katsura
Nagai, Aiko
Murai, Taro
Miyakawa, Akifumi
author_facet Baba, Fumiya
Shibamoto, Yuta
Ogino, Hiroyuki
Murata, Rumi
Sugie, Chikao
Iwata, Hiromitsu
Otsuka, Shinya
Kosaki, Katsura
Nagai, Aiko
Murai, Taro
Miyakawa, Akifumi
author_sort Baba, Fumiya
collection PubMed
description BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung cancer (NSCLC) treated with different doses depending on tumor diameter. METHODS: Between February 2004 and November 2008, 124 patients with stage I NSCLC underwent SBRT. Total doses of 44, 48, and 52 Gy were administered for tumors with a longest diameter of less than 1.5 cm, 1.5-3 cm, and larger than 3 cm, respectively. All doses were given in 4 fractions. RESULTS: For all 124 patients, overall survival was 71%, cause-specific survival was 87%, progression-free survival was 60%, and local control was 80%, at 3 years. The 3-year overall survival was 79% for 85 stage IA patients treated with 48 Gy and 56% for 37 stage IB patients treated with 52 Gy (p = 0.05). At 3 years, cause-specific survival was 91% for the former group and 79% for the latter (p = 0.18), and progression-free survival was 62% versus 54% (p = 0.30). The 3-year local control rate was 81% versus 74% (p = 0.35). The cumulative incidence of grade 2 or 3 radiation pneumonitis was 11% in stage IA patients and 30% in stage IB patients (p = 0.02). CONCLUSIONS: There was no difference in local control between stage IA and IB tumors despite the difference in tumor size. The benefit of increasing the SBRT dose for larger tumors should be investigated further.
format Text
id pubmed-2955592
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29555922010-10-16 Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size Baba, Fumiya Shibamoto, Yuta Ogino, Hiroyuki Murata, Rumi Sugie, Chikao Iwata, Hiromitsu Otsuka, Shinya Kosaki, Katsura Nagai, Aiko Murai, Taro Miyakawa, Akifumi Radiat Oncol Research BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung cancer (NSCLC) treated with different doses depending on tumor diameter. METHODS: Between February 2004 and November 2008, 124 patients with stage I NSCLC underwent SBRT. Total doses of 44, 48, and 52 Gy were administered for tumors with a longest diameter of less than 1.5 cm, 1.5-3 cm, and larger than 3 cm, respectively. All doses were given in 4 fractions. RESULTS: For all 124 patients, overall survival was 71%, cause-specific survival was 87%, progression-free survival was 60%, and local control was 80%, at 3 years. The 3-year overall survival was 79% for 85 stage IA patients treated with 48 Gy and 56% for 37 stage IB patients treated with 52 Gy (p = 0.05). At 3 years, cause-specific survival was 91% for the former group and 79% for the latter (p = 0.18), and progression-free survival was 62% versus 54% (p = 0.30). The 3-year local control rate was 81% versus 74% (p = 0.35). The cumulative incidence of grade 2 or 3 radiation pneumonitis was 11% in stage IA patients and 30% in stage IB patients (p = 0.02). CONCLUSIONS: There was no difference in local control between stage IA and IB tumors despite the difference in tumor size. The benefit of increasing the SBRT dose for larger tumors should be investigated further. BioMed Central 2010-09-17 /pmc/articles/PMC2955592/ /pubmed/20849623 http://dx.doi.org/10.1186/1748-717X-5-81 Text en Copyright ©2010 Baba et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Baba, Fumiya
Shibamoto, Yuta
Ogino, Hiroyuki
Murata, Rumi
Sugie, Chikao
Iwata, Hiromitsu
Otsuka, Shinya
Kosaki, Katsura
Nagai, Aiko
Murai, Taro
Miyakawa, Akifumi
Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title_full Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title_fullStr Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title_full_unstemmed Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title_short Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
title_sort clinical outcomes of stereotactic body radiotherapy for stage i non-small cell lung cancer using different doses depending on tumor size
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955592/
https://www.ncbi.nlm.nih.gov/pubmed/20849623
http://dx.doi.org/10.1186/1748-717X-5-81
work_keys_str_mv AT babafumiya clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT shibamotoyuta clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT oginohiroyuki clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT muratarumi clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT sugiechikao clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT iwatahiromitsu clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT otsukashinya clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT kosakikatsura clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT nagaiaiko clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT muraitaro clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize
AT miyakawaakifumi clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize